Metreleptin for treating lipodystrophy

took into account the impact of metreleptin beyond direct health benefits (see section 4.31) and the likely overestimated cost-effectiveness results (see section 4.14 and section 4.35). As such, the committee agreed that the ICER of Â£108,267 per QALY gained would lower to an acceptable range for metreleptin to be an effective use of NHS resources. Therefore, the committee concluded that metreleptin can be considered a cost-effective use of NHS resources for highly specialised technologies, and recommended metreleptin as an option for treating the complications of leptin deficiency in lipodystrophy for people who are either 2 years and over with generalised lipodystrophy, or 12 years and over with partial lipodystrophy with HbA1c above 58 mmol/mol (7.5%), or fasting triglycerides above 5.0 mmol/litre, or both. 5 Implementation 5.1 Section 8(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of publication. 5.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE highly specialised
